External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease

Pediatric Infectious Disease Journal

Volumn 30, Issue 2, 2011, Pages 145-147

  Seki, Mitsuru ^a,b   Kobayashi, Tohru ^a   Kobayashi, Tomio ^b   Morikawa, Akihiro ^a   Otani, Tetsuya ^c   Takeuchi, Kazuo ^d   Ayusawa, Mamoru ^e   Tsuchiya, Keiji ^f   Yasuda, Kenji ^g   Suzuki, Takahiro ^a   Shimoyama, Shinya ^b   Ikeda, Kentaro ^b   Ishii, Yoichiro ^a   Arakawa, Hirokazu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gumna Children S Medical Center   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d SAITAMA UNIVERSITY   (Japan)

^e NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^g SHIMANE UNIVERSITY   (Japan)

Author keywords

coronary artery abnormalities; relapse; risk score; treatment failure

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CHILD; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE COMPARISON; EXTERNAL VALIDITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; RISK SCORE; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 79551601458     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f386db     Document Type: Article

References (12)

1. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-1385.
2. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
3. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:E78.
4. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
5. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606-2612.
6. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (5th revised edition). Pediatr Int. 2005;47:232-234.
7. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533-544.
8. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142:611-616.
9. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999;135:465-469.
10. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.
11. Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. Pediatr Infect Dis J. 2009;28:498-502.
12. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immuno-globulin in children with Kawasaki disease. J Pediatr. 2008;153:117-121.